Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemiaFinancial support: This study was funded by Daiichi Sankyo Company Ltd and Eli Lilly and Company.
26 September 2016
Accepted after major revision: 16 November 2016
22 November 2017 (online)
Patients with sickle cell anaemia (SCA) have vaso-occlusive crises resulting from occlusive hypoxic-ischaemic injury. Prasugrel inhibits platelet activation and aggregation involved in SCA pathophysiology. Determining Effects of Platelet Inhibition on Vaso-Occlusive Events (DOVE) was a phase 3, double-blind, randomised, placebo-controlled trial assessing prasugrel efficacy. DOVE sought to bring patients’ P2Y12 reaction unit (PRU) value within a targeted range via prasugrel dose adjustments using encrypted VerifyNow P2Y12® (VN-P2Y12) point-of-care testing and an interactive voice-response system (IVRS). After PRU determination, randomised patients received 0.08 mg/kg/day prasugrel or placebo. Encrypted PRUs and IVRS provided double-blind dose adjustments to achieve a defined PRU target range of 136–231; placebo patients had mock titrations. Of 341 randomised patients, 166 placebo and 160 prasugrel patients reached the fully titrated dose (FTD). Most prasugrel patients (n=104, 65 %) remained on the initial 0.08 mg/kg dose; doses escalations occurred in 23 % of patients (n=36). Mean PRUs for the pharmacodynamic population at baseline were similar in the prasugrel (273 ± 44.9) and placebo groups (273 ± 51.7), with significant reductions in PRU (p<0.001) for prasugrel patients at the FTD and at 9 months. Concomitant use of hydroxyurea did not affect platelet reactivity at any time. The majority of prasugrel patients (n=135, 84.4 %) at the FTD were within the target range of 136–231 PRUs. Mean VN-P2Y12 percentage inhibition at baseline was similar in the prasugrel (2.8 ± 5.4 %) and placebo groups (2.0 ± 4.7 %); prasugrel patients had significant increases in inhibition (p<0.001) at FTD and at 9 months. Patients with higher PRU values at baseline required higher prasugrel doses to bring PRU within the prespecified range. DOVE is the first study to successfully employ double-blind, real-time, encrypted, point-of-care platelet testing and IVRS to dose-adjust antiplatelet therapy to a targeted range of platelet inhibition.
- 1 Serjeant GR. Sickle-cell disease. Lancet 1997; 350: 725-730.
- 2 Niitsu Y, Jakubowski JA, Sugidachi A. et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31: 184-194.
- 3 Jakubowski JA, Winters KJ, Naganuma H. et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
- 4 Jakubowski JA, Zhou C, Small DS. et al. A Phase 1 Study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol 2013; 75: 1433-1444.
- 5 Jakubowski JA, Zhou C, Jurcevic S. et al. A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation. Thromb Res 2014; 133: 190-195.
- 6 Wun T, Soulieres D, Frelinger AL. et al. A double-blind, randomized, multicentre phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013; 06: 17-26.
- 7 Hoppe CC, Styles L, Heath LE. et al. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) Trial: a global phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose-titration strategy. Pediatr Blood Cancer 2016; 63: 299-305.
- 8 Heeney MM, Hoppe CC, Abboud MR. et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med 2016; 374: 625-635.
- 9 Frelinger 3rd AL, Michelson AD, Wiviott SD. et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226.
- 10 Styles L, Heiselman D, Heath LE. et al. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol 2015; 37: 1-9.
- 11 Jakubowski JA, Payne CD, Li YG. et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
- 12 Effient (package insert). Indianapolis, IN: Eli Lilly and Company; 2016. Available at http://uspl.lilly.com/effient/effient.html#pi Accessed August 10, 2016.
- 13 Collet JP, Cayla G, Cuisset T. et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011; 161: 5.e5-12.e5.
- 14 Cayla G, Cuisset T, Silvain J. et al. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. Am Heart J 2014; 168: 674-681.
- 15 Price MJ, Berger PB, Angiolillo DJ. et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009; 157: 818-824.e1.
- 16 Li JS, Yow E, Berezny KY. et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation 2008; 117: 553-559.
- 17 Wessel DL, Berger F, Li JS. et al. A randomized trial of clopidogrel to reduce mortality and shunt-related morbidity in infants palliated with a systemic to pulmonary artery shunt. Circulation 2010; 122: 21.
- 18 Cabannes R, Lonsdorfer J, Castaigne JP. et al. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984; 15: 213-221.
- 19 Semple MJ, Al-Hasani SF, Kioy P. et al. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984; 51: 303-306.
- 20 Gurbel PA, Bliden KP, Hiatt B. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
- 21 Tantry US, Bonello L, Aradi D. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.